Rochester Medical Corp. reported unaudited earnings results for the fourth quarter and year ended September 30, 2009. The company reported sales of $9,009,000 for the current quarter compared to $9,512,000 for the fourth quarter of last year. The company reported a quarterly net loss of $229,000 or $0.02 loss per diluted share compared to net income of $342,000 or $0.03 per diluted share for the fourth quarter of last year. The approximate 5% decrease in sales (0.6% decrease on a constant currency basis) resulted from a 2% increase in Rochester Medical Branded Sales (10% increase on a constant currency basis), offset by a 20% decrease in Private Label Sales (20% decrease on a constant currency basis). Net income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or 'Non-GAAP Net Income' for the current quarter was $95,000 or $0.01 per diluted share compared to Non-GAAP Net Income of $658,000 or $0.05 per diluted share for the fourth quarter of last year. The decrease for the current quarter on a Non-GAAP basis is primarily attributable to the impact of exchange rate variation and increased investment in Sales and Marketing programs. For the quarter, the company reported loss from operations of $173,434 and net loss before income taxes of $172,356 compared to income from operations of $321,768 and net loss before income taxes of $348,449 for the same period a year ago. For the fiscal year ended September 30, 2009, the Company reported sales of $34,799,000 compared to sales of $35,192,000 for the previous year. It reported net income for the year of $109,000 or $0.01 per diluted share compared to net income of $759,000 or $0.06 per diluted share for the previous year. The approximate 1% decrease in annual sales (7% increase on a constancy currency basis) resulted from a 2% decrease in Rochester Medical Branded Sales (10% increase on a constant currency basis) partially offset by a 2% increase in Private Label Sales (2% increase on a constant currency basis). Non-GAAP Net Income for the current year was $865,000 or $0.07 per diluted share compared to Non-GAAP Net Income of $2,174,000 or $0.17 per diluted share for the previous year. The decrease for the current year on a Non-GAAP basis is primarily due to the impact of exchange rate variation and increased investment in Sales and Marketing. It is also due to a tax benefit of $654,000 taken in the third quarter of last year and higher interest income in the prior year. For the nine months, the company reported loss from operations of $749,882 and net income before income taxes of $474,414 compared to loss from operations of $492,839 and net loss before income taxes of $180,648 for the same period a year ago.

Rochester Medical Corp., Q4 2009 Earnings Call, Nov-05 2009

Rochester Medical Corp. announced the introduction of its Strata brands of Foley catheters. This new Foley product line features proprietary comfort layered technology. The company's StrataSI(TM) catheter is all-silicone, while the StrataNF(TM) version includes a nitrofurazone anti-infective matrix within the silicone. Comfort is the primary area of focus for the StrataSI(TM) and StrataNF(TM) products; the improved silicone design consists of a soft, pliable inner core surrounded by ultra-soft, ultra-smooth outer layers. The new structure allows for softness and flexibility never before seen in an all-silicone catheter. The StrataNF(TM) catheter provides the gentle feel of StrataSI(TM) along with anti-infection properties that are clinically proven to reduce bacterial CAUTI. The development of the Strata Foley catheters continues Rochester Medical's long history of bringing revolutionary and innovative silicone elastomer products to the urological market.